Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU

Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne

Astec LifeSciences Q1 FY26 revenue up 30.3%

The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr

Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

Torrent Pharma launches nutrition supplement powder Shelcal Total

Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio